CDRH Accelerates Software Development To Improve Collaboration With Industry
This article was originally published in The Gray Sheet
Executive Summary
FDA’s device center hopes the effort, which is intended to model a quicker-turnaround “Silicon Valley” approach to system development, will help reduce time-to-market for new devices, and simplify some post-market surveillance efforts.
You may also be interested in...
CDRH Entrepreneurs Take Two: Streamlining Data Collection And The Path To Reimbursement
FDA’s device center launched the second round of its entrepreneurs-in-residence program, bringing in outside experts to the center to focus on streamlining data collection and the approval-to-reimbursement pathway.
FDA Releases Proposed Rule On UDI System, Ushering in ‘Modern Post-Market Surveillance System’
A proposed FDA regulation for a Unique Device Identification System is critical to the future of post-market safety surveillance, the agency says. The UDI system aims to reduce medical errors, and provide an array of other benefits for supply chain management. Makers of high-risk class III products will have one year to place UDI codes on devices. The UDI mandate will extend to moderate-risk class II devices two years later and to some low-risk class I devices two years after that.
CDRH Launches ‘Innovation Pathway 2.0’ With End-Stage Renal Devices
Participants expect the program to tangibly reduce time to market and improve companies’ prospects for raising money.